Long-lasting control of triple-negative metastatic breast cancer with the novel drug combination ixabepilone and capecitabine - Case report

Onkologie

Volumn 33, Issue 1-2, 2010, Pages 53-56

  Vrdoljak, Eduard ^a   Miše, Branka Petrić ^a   Lukić, Blanka ^b   Curić, Zvonimir ^c   Bošković, Lidija ^a   Tica, Ivana ^b  

^a UNIVERSITY HOSPITAL SPLIT   (Croatia)

^b UNIVERSITY OF MOSTAR   (Bosnia and Herzegovina)

^c General Hospital Dubrovnik   (Croatia)

Author keywords

Ixabepilone; Metastatic breast cancer; Peripheral neuropathy; Taxane

Indexed keywords

CAPECITABINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; IXABEPILONE; METHOTREXATE; PACLITAXEL;

ADULT; ARTICLE; AXILLARY LYMPH NODE; BLOOD TOXICITY; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER REGRESSION; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; EVENING DOSAGE; FEMALE; GRANULOCYTOPENIA; HAND FOOT SYNDROME; HUMAN; LUNG METASTASIS; LYMPH NODE DISSECTION; MASTECTOMY; MORNING DOSAGE; MULTIPLE CYCLE TREATMENT; NAIL; PERIPHERAL NEUROPATHY; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL; CARCINOMA, PAPILLARY; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EPOTHILONES; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; LONG-TERM CARE; LUNG NEOPLASMS; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 77249129060     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000264615     Document Type: Article

References (35)

1. International Agency for Research on Cancer: www-dep.iarc.fr/.
2. Er O, Frye DK, Kau SW, Broglio K, Valero V, Hortobagyi GN, Arun B: Clinical course of breast cancer patients with metastases limited to the liver treated with chemotherapy. Cancer J 2008;4:62-8.
3. Valero V, Hortobagyi GN: Are anthracycline-taxane regimens the new standard of care in the treatment of metastatic breast cancer? J Clin Oncol 2003;21:959-62.
4. Longley DB, Johnston PG: Molecular mechanisms of drug resistance. J Pathol 2005;205:275-92.
5. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lønning P, Børresen-Dale AL: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98:10869.
6. Cleator S, Heller W, Coombes RC: Triple-negative breast cancer: therapeutic options. Lancet Oncol 2007;26:235-44.
7. Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Henessy B, Green M, Cristofanilli M, Hortobagyi GN, Pusztai L: Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008;26:1275-81.
8. Reis-Filho JS, Tutt AN: Triple negative tumors: a critical review. Histopathology 2008;52:108-18.
9. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA: Triple negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007;13:4429-34.
10. Shiu KK, Tan DS, Reis-Filho JS: Development of therapeutic approaches to 'triple negative' phenotype breast cancer. Expert Opin Ther Targets 2008;12:1123-37.
11. Pivot X, Dufresne A, Villanueva C: Efficacy and safety of ixabepilone, a novel epothilone analog. Clin Breast Cancer 2007;7:543-9.
12. Cortes J, Baselga J: Targeting the microtubules in breast cancer beyond taxanes: the epothilones. Oncologist 2007;12:271-80.
13. Lee FY, Borzilleri R, Fairchild CR, Kim SH, Long BH, Reventos-Suarez C, Vite GD, Rose WC, Kramer RA: BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 2001;7:1429-37.
14. Altmann KH, Wartmann M, O'Reilly T: Epothilones and related structures-a new class of microtubule inhibitors with potent in vivo antitumor activity. Biochem Biophys Acta 2000;1470:M79-M91.
15. Altmann KH: The chemistry and biology of epothilones-lead structures for the discovery of improved microtubule inhibitors; in Liang XT, Fang WS (eds): Medicinal Chemistry of Bioactive Natural Products. Hoboken, NJ, Wiley and Sons, 2006, pp.1-34.
16. Hortobagyi GN, Perez E, Vrdoljak E, Medina C, Xu B, Sparano P: Analysis of overall survival among patients with mBC receiving either ixabepilone plus capecitabine or capecitabine alone - phase III trial. Proc ASCO Breast 2008; abst 186.
17. Roche H, Li R, et al.: Ixabepilone plus capecitabine improves progression free survival in patients with metastatic breast cancer resistant to taxanes: pooled analysis from two phase III trials. San Antonio Breast Cancer Symposium 2008;poster 2015.
18. Rugo HS, Thomas ES, et al.: Combination therapy with the novel epothilone B analog, ixabepilone, plus capecitabine has efficacy in ER/PR/HER2-negative breast cancer resistant to anthracyclines and taxanes. San Antonio Breast Cancer Symposium 2007;poster 6069.
19. Therasse P, Arbuck SG, Eisenhauer EA, et al.: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
20. Cancer Therapy Evaluation Program, National Cancer Institute: Common terminology criteria for adverse events v.3.0 (CTCAE). ctep.cancer.gov/ protocolDevelopment/electronic-applications/docs/ ctcaev3.pdf. accessed 8 May 2008.
21. Crown J: Metastatic breast cancer: why are we here and where are we going ? Eur J Cancer 2006;4:2-5.
22. O'Shaughnessy J: Extending survival with chemotherapy in metastatic breast cancer. Oncologist 2005;10:20-9.
23. Beslija S, Bonneterre J, Burstein H, Cocquyt V, et al.: Second consensus on medical treatment of metastatic breast cancer. Ann Oncol 2007;18: 215-25.
24. Wartmann M, Altmann KH: The biology and medicinal chemistry of epothilones. Curr Med Chem Anticancer Agents 2002;2:123-48.
25. Lee F, Camuso A, Castenada S: Preclinical studies of ixabepilone (BMS-247550) demonstrate optimal antitumor activity against both chemotherapy-sensitive and resistant tumor types. Proc Am Assoc Cancer Res 2006;47:19.
26. Jordan MA, Miller H, Ni L, et al.: The Pat-21 breast cancer model derived from a patient with primary Taxol® resistance recapitulates the phenotype of its origin, has altered β-tubulin expression and is sensitive to ixabepilone. Proc Am Assoc Cancer Res 2006;47:abstr LB-280.
27. Perez EA, Lerzo G, Pivot X, Thomas E, Vahdat L, Bosserman L, Viens P, Cai C, Mullaney B, Peck R, Hortobagyi GN: Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 2007;25:3407-14.
28. Thomas E, Tabernero J, Fornier M, Conte P, Fumoleau P, Lluch A, Vahdat LT, Bunnell CA, Burris HA, Viens P, Baselga J, Rivera E, Guarneri V, Poulart V, Klimovsky J, Lebwohl D, Martin M: Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxaneresistant metastatic breast cancer. J Clin Oncol 2007;25:3399-406.
29. Low JA, Wedam SB, Lee JJ, Berman AW, Brufsky A, Yang SX, Poruchynsky MS, Steinberg SM, Mannan N, Fojo T, Swain SM: Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol 2005;23:2726-34.
30. Thomas ES, Gomez HL, Li RK, Chung HC, Fein LE, Chan VF, Jassem J, Pivot XB, Klimovsky JV, de Mendoza FH, Xu B, Campone M, Lerzo GL, Peck RA, Mukhopadhyay P, Vahdat LT, Roche HH: Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2007;25:5210-7.
31. Pivot X: Phase III study of ixabepilone plus capecitabine in patients with metastatic breast cancer (MBC) resistant to anthracycline/taxanes: subgroup analysis by estrogen receptor (ER) status. Breast Cancer Symposium ASCO 2007;abst 221.
32. Stockler M, Wilcken NJC, Coates AS: Chemotherapy for advanced breast cancer-how long should it continue? Breast Cancer Res Treat 2003;81:49-52.
33. Zielinski C, Beslija S, Mrsic-Krmpotic Z, Welnicka-Jaskiewicz M, Wiltschke C, Kahan Z, Grgic M, Tzekova V, Inbar M, Cervek J, Chernozemsky I, Szanto J, Spanik S, Wagnerova M, Ghilezan N, Pawlega J, Vrbanec D, Khamtsov D, Soldantekova V, Brodowicz T: Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: a Central European Cooperative Oncology Group International, multicenter, prospective randomized phase III trial. J Clin Oncol 2005;23:1401-8.
34. O'Shaughnessy, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, Fumoleau P, Jones S, Lui WY, Mauriac L, Twelves C, Van Hazel G, Verma S, Leonard R: Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002;20:2812-23.
35. Jassem J, Pienkowski T, Pluzanska A, Jelic S, Gorbunova V, Mrsic-Krmpotic Z, Berzins J, Nagykalnai T, Wigler N, Renard J, Munier S, Weil C, Central and Eastern Europe and Israel Paclitaxel Breast Cancer Study Group: Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a rando mized phase III multicenter trial. J Clin Oncol 2001;19:1707-15.